BioCentury | Dec 5, 2019
Emerging Company Profile

VaxNewMo: bioconjugating antibacterial vaccines

...the only one that can transfer pneumococcal and Klebsiella polysaccharides. Several companies including SutroVax Inc., Vaxxilon AG...
...on the carrier protein; its lead product is a 24-valent pneumococcal vaccine in preclinical development. Vaxxilon AG...
BioCentury | Feb 16, 2018
Emerging Company Profile

Synthetic speed

...vaccines. “It’s an order of magnitude different in terms of capital investment and potentially time,” Vaxxilon...
...prevent pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains. Monroe told BioCentury Vaxxilon...
...Vaxxilon to Idorsia Ltd. upon its acquisition by Johnson & Johnson last year. COMPANY PROFILE Vaxxilon AG...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Infectious disease

...increased serum titers of opsonizing antibodies compared with immunization with Prevenar 13. Next steps by Vaxxilon AG...
...disease. TARGET/MARKER/PATHWAY: Streptococcus pneumoniae capsular polysaccharide ( S. pneumoniae CPS) LICENSING STATUS: Patented; licensed to Vaxxilon AG...
...doi:10.1073/pnas.1706875114 CONTACT: Claney L. Pereira, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany email: claney.pereira@vaxxilon.com...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Infectious disease

...Colloids and Interfaces, Potsdam, Germany email: peter.seeberger@mpikg.mpg.de CONTACT: Claney Pereira, same affiliation as above email: claney.pereira@vaxxilon.com Lauren...
BioCentury | Aug 26, 2016
Company News

Management tracks

...Vaccine developer Vaxxilon AG (Reinach, Switzerland) named Arne von Bonin CSO. He was CSO at Affiris AG...
BioCentury | Jul 20, 2015
Company News

Max Planck Society, Vaxxilon deal

...Max Planck and Actelion Ltd. (SIX:ATLN, Allschwil, Switzerland) launched Vaxxilon. The company has exclusive, worldwide rights...
...exclusive, worldwide rights to multiple preclinical vaccine candidates targeting undisclosed bacterial pathogens from Max Planck. Vaxxilon...
...into Vaxxilon over the next three to four years. Actelion executive Tom Monroe will lead Vaxxilon...
BioCentury | Jun 27, 2015
Company News

Actelion, Max Planck launch vaccine play Vaxxilon

...Max Planck Society launched Vaxxilon AG (Reinach, Switzerland), a newco focused on developing synthetic carbohydrate vaccines. Vaxxilon...
...into Vaxxilon over the next three to four years. Actelion executive Tom Monroe will lead Vaxxilon...
Items per page:
1 - 7 of 7
BioCentury | Dec 5, 2019
Emerging Company Profile

VaxNewMo: bioconjugating antibacterial vaccines

...the only one that can transfer pneumococcal and Klebsiella polysaccharides. Several companies including SutroVax Inc., Vaxxilon AG...
...on the carrier protein; its lead product is a 24-valent pneumococcal vaccine in preclinical development. Vaxxilon AG...
BioCentury | Feb 16, 2018
Emerging Company Profile

Synthetic speed

...vaccines. “It’s an order of magnitude different in terms of capital investment and potentially time,” Vaxxilon...
...prevent pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains. Monroe told BioCentury Vaxxilon...
...Vaxxilon to Idorsia Ltd. upon its acquisition by Johnson & Johnson last year. COMPANY PROFILE Vaxxilon AG...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Infectious disease

...increased serum titers of opsonizing antibodies compared with immunization with Prevenar 13. Next steps by Vaxxilon AG...
...disease. TARGET/MARKER/PATHWAY: Streptococcus pneumoniae capsular polysaccharide ( S. pneumoniae CPS) LICENSING STATUS: Patented; licensed to Vaxxilon AG...
...doi:10.1073/pnas.1706875114 CONTACT: Claney L. Pereira, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany email: claney.pereira@vaxxilon.com...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Infectious disease

...Colloids and Interfaces, Potsdam, Germany email: peter.seeberger@mpikg.mpg.de CONTACT: Claney Pereira, same affiliation as above email: claney.pereira@vaxxilon.com Lauren...
BioCentury | Aug 26, 2016
Company News

Management tracks

...Vaccine developer Vaxxilon AG (Reinach, Switzerland) named Arne von Bonin CSO. He was CSO at Affiris AG...
BioCentury | Jul 20, 2015
Company News

Max Planck Society, Vaxxilon deal

...Max Planck and Actelion Ltd. (SIX:ATLN, Allschwil, Switzerland) launched Vaxxilon. The company has exclusive, worldwide rights...
...exclusive, worldwide rights to multiple preclinical vaccine candidates targeting undisclosed bacterial pathogens from Max Planck. Vaxxilon...
...into Vaxxilon over the next three to four years. Actelion executive Tom Monroe will lead Vaxxilon...
BioCentury | Jun 27, 2015
Company News

Actelion, Max Planck launch vaccine play Vaxxilon

...Max Planck Society launched Vaxxilon AG (Reinach, Switzerland), a newco focused on developing synthetic carbohydrate vaccines. Vaxxilon...
...into Vaxxilon over the next three to four years. Actelion executive Tom Monroe will lead Vaxxilon...
Items per page:
1 - 7 of 7